Drug Profile
LY 3200327
Alternative Names: LY3200327Latest Information Update: 28 Dec 2018
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Dec 2018 No recent reports of development identified for clinical-Phase-Unknown development in Unspecified(In volunteers) in USA (IV, Injection)
- 28 Dec 2018 No recent reports of development identified for clinical-Phase-Unknown development in Unspecified(In volunteers) in USA (SC, Injection)
- 02 Nov 2015 Eli Lilly plans a phase I trial in Healthy volunteers in USA (NCT02595736)